PROGNOSTIC FACTORS FOR THE RESPONSE TO TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS: A COHORT STUDY

PROGNOSTIC FACTORS FOR THE RESPONSE TO TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS: A COHORT STUDY

Background. To assign genetically engineered biologic drugs, we need data on the predictors for response to therapy. Prognostic factors for the response to tocilizumab in patients with juvenile idiopathic arthritis (JIA) without systemic symptoms are poorly studied.Objective. Our aim was to reveal e...

Full description

Bibliographic Details
Main Authors: Ekaterina I. Alexeeva, Tatyana M. Dvoryakovskaya, Kseniya B. Isaeva, Tatyana V. Sleptsova, Rina V. Denisova, Margarita A. Soloshenko, Olga L. Lomakina, Anna N. Fetisova, Mariya G. Rudnickaya, Dariya D. Vankova, Alina A. Alshevskaya, Andrei V. Moskalev, Anna V. Mamutova
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2018-07-01
Series:Voprosy Sovremennoj Pediatrii
Subjects:
children
juvenile idiopathic arthritis
therapy
response predictors
genetically engineered biologic drug
tocilizumab
Online Access:https://vsp.spr-journal.ru/jour/article/view/1900

Internet

https://vsp.spr-journal.ru/jour/article/view/1900

Similar Items